Neurosearch denies share manipulation charges
COPENHAGEN (Reuters) - Danish biopharma firm Neurosearch A/S said on Wednesday charges of share price manipulation had been filed against it, but it denied the allegations and said it was working with the authorities to clear up the matter.
Neurosearch said the charges were related to an announcement in February 2010 in which the management of the company reported top-line results from a Phase III study with its Huntington's disease drug candidate Huntexil and then two months later reassessed and corrected the data in a new announcement.
"On the present basis, Neurosearch is denying the charges and is collaborating fully with the authorities in order to resolve the matter," the company said in a statement.
(Reporting by John Acher)
- Tweet this
- Share this
- Digg this
- UPDATE 3-U.S. regulator questions Verizon plan to slow data speeds for some
- Argentina credit story grows murkier as talks collapse
- U.S. man sues soccer star Cristiano Ronaldo over CR7 trademark
- Best Buy CEO says tablet sales are "crashing" - Re/code
- Kerry presses India on global trade deal as deadline looms